MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
NTLA Intellia Therapeutics
- 12.180
- +0.100+0.83%
Close Dec 20 16:00 ET
- 12.446
- +0.266+2.18%
Post 20:01 ET
1.24BMarket Cap-2.23P/E (TTM)
12.450High11.850Low3.69MVolume11.940Open12.080Pre Close45.02MTurnover3.67%Turnover RatioLossP/E (Static)101.85MShares34.87052wk High1.29P/B1.22BFloat Cap11.79052wk Low--Dividend TTM100.57MShs Float202.730Historical High--Div YieldTTM4.97%Amplitude9.180Historical Low12.213Avg Price1Lot Size
About Intellia Therapeutics Company
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Company Profile
SymbolNTLA
Company NameIntellia Therapeutics
Listing DateMay 6, 2016
Issue Price18.00
Founded2014
CEODr. John M. Leonard, M.D.
MarketNASDAQ
Employees526
Fiscal Year Ends12-31
Address40 Erie Street,Suite 130
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139
Phone1-857-285-6200
Websitehttp://www.intelliatx.com
Company Executives
- Name
- Position
- Salary
- Dr. John M. Leonard, M.D.
- Director, President and Chief Executive Officer
- 11.66M
- Eliana Clark
- Executive Vice President and Chief Technology Officer
- --
- Derek Hicks
- Executive Vice President and Chief Business Officer
- --
- Edward J. Dulac, III
- Treasurer, Executive Vice President and Chief Financial Officer
- --
- Dr. Laura Sepp-Lorenzino, PhD
- Executive Vice President and Chief Scientific Officer
- 4.19M
- Dr. David Lebwohl, M.D.
- Executive Vice President and Chief Medical Officer
- 4.26M
- James Basta, J.D.
- Executive Vice President, General Counsel and Corporate Secretary
- 3.99M
- Dr. Frank Verwiel, M.B.A.,M.D.
- Chairman of the Board
- 499.94K
- Dr. Fred E. Cohen, D.Phil.,F.A.C.P.,M.D.
- Independent Director
- 452.44K
- Brian Goff
- Independent Director
- --
- William J. Chase
- Independent Director
- 996.21K
- Dr. Jesse Goodman, M.D.,M.P.H.
- Independent Director
- 449.94K
- Muna Bhanji, Ph.
- Independent Director
- 455.25K
- Dr. Georgia Keresty, M.P.H.,PhD
- Independent Director
- 454.94K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
